ABSTRACT
Background The objective of this rapid scoping review was to identify potentially safe and effective dose-sparing strategies for intramuscular administration of seasonal influenza vaccines in healthy individuals of all ages.
Methods Comprehensive literature searches were developed and executed in MEDLINE, EMBASE, and the Cochrane library, and grey literature was searched via international clinical trial registries for relevant studies published in English in the last 20 years. References of relevant systematic reviews and included studies were also scanned. Title/abstract and full-text screening were carried out by pairs of reviewers independently and data charting conducted by a single reviewer and verified by a second reviewer. Results were presented narratively.
Results A total of 13 studies with 10,351 participants were included in the review and all studies were randomized control trials conducted between 2006 and 2019. The most common interventions were the trivalent influenza vaccine (n=10), followed by quadrivalent influenza vaccine (n=4). Nine studies included infants/toddlers 6-36 months old and one of these studies also included children and adolescents. In these nine studies, no clinical effectiveness outcomes were reported and no difference was found in local and systemic reactogenicity between dosing strategies. Of the four adult studies (≥ 18 years), the two studies that reported on effectiveness outcomes found similar results between the half-dose and full-dose vaccination groups and all four studies reported no differences in safety outcomes between groups.
Conclusion The current evidence for the administration of intramuscular influenza vaccines suggests there is no significant difference in safety and clinical effectiveness with the use of low-dose compared to full-dose vaccines, which is promising given the predicted resource constraints in the upcoming influenza season due to the 2019 novel coronavirus. Due to the low number of studies in adults and the lack of studies assessing confirmed influenza and influenza-like illness, there remains a need for further evaluation.
PURPOSE The Centre for Immunization and Respiratory Infectious Diseases of the Public Health Agency of Canada (PHAC) submitted a query regarding the safety and effectiveness of fractional dosing of seasonal influenza vaccines through the Canadian Institutes of Health Research (CIHR) Drug Safety and Effectiveness Network (DSEN). They requested that the DSEN Methods and Application Group in Indirect Comparisons (MAGIC) conduct a rapid review on this topic with an approximate 6-week timeline.
The overall objective of this rapid review was to identify potentially safe and effective dose-sparing strategies for administration of seasonal influenza vaccines in healthy individuals of all ages that have been evaluated in human trials. In order to limit the scope of the work and ensure the rapid timeline could be met, this review focused only on intramuscular vaccine formulations, thus the research question was as follows:
What is the safety and effectiveness of using fractional dosing strategies to deliver intramuscular seasonal influenza vaccines?
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported through the Drug Safety and Effectiveness Network funded by the Canadian Institutes of Health Research. ACT is funded by a Tier 2 Canada Research Chair in Knowledge Synthesis and SES is funded by a Tier 1 Canada Research Chair in Knowledge Translation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
For questions about this report, please contact: Andrea Tricco, MSc, PhD, NPI, MAGIC Team, Drug Safety and Effectiveness Network, Canadian Institutes of Health Research, Director, Knowledge Synthesis Team, Knowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Toronto, Canada, Email: Andrea.Tricco{at}unityhealth.to, Phone: 416-864-6060 ext. 77521
Data Availability
All datasets supporting the conclusions of this article are included within the article.
